Little Willow had formula made at a Michigan plant and sold at a Walmart more than a year after Abbott was placed under court-mandated oversight by the FDA.

The parents of a Kentucky baby who died last fall after drinking bacteria-tainted infant formula are the latest to sue Abbott Nutrition, the manufacturer at the heart of a 2022 crisis that left millions of Americans scrambling to feed their children. Willow Jade Dellaquila, of Carrollton, Kentucky, was 13 days old when she died on Nov. 5, 2023. She was infected with cronobacter sakazakii, a dangerous germ traced to a can of Similac Total Comfort powdered formula used in the baby’s bottles, records show. “They told me she had a stroke on her right side of the brain,” Cheyenne Ping, Willow’s 25-year-old mother, said in an interview. “It’s really heartbreaking. No one should have to go through this.” Ping and the baby’s 26-year-old father, Christian Dellaquila, can move forward with a lawsuit against Abbott, an Illinois judge ruled Wednesday. The couple had previously sought to join a lawsuit with two other families who say their children suffered devastating brain damage caused by cronobacter linked to a different type of Abbott powdered formula, Similac Neosure.

Karen Firestone, chairman and CEO at Aureus Asset Management, joins CNBC''s "Halftime Report" to detail her latest portfolio moves.

We recently compiled a list of the 10 Best Organ Transplant and Diagnosis Stocks To Buy Now. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other organ transplant and diagnosis stocks. In the dynamic landscape of healthcare, the importance of organ transplantation cannot be overstated. Transplant […]

Abbott Labs to collaborate with Cadrenal Therapeutics on tecarfarin anticoagulant trial for patients with implanted cardiac devices. Read more here.

No summary available.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock''s price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let''s see what these Wall Street heavyweights think about Abbott (NYSE: ABT ). Abbott currently has an average brokerage recommendation of 1.50, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 20 brokerage firms. An ABR of 1.50 approximates between Strong Buy and Buy. Of the 20 recommendations that derive the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70% and 10% of all recommendations. Brokerage Recommendation Trends for ABT While the ABR calls for buying Abbott, it may not be wise to make an investment decision solely based on this information.

''Mad Money'' host Jim Cramer shares his take on the Abbott Labs verdict.

Will McGough, Prime Capital Investment Advisors director of investments, joins ''Power Lunch'' to discuss stock plays for three stocks.

Abbott Laboratories shares came under pressure Monday after a jury in St. Louis ruled on Friday that the company must pay $495 million in compensation and damages in a lawsuit involving the company''s premature infant formula.